The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 ...
The US Food and Drug Administration (FDA) has expanded the indication for the more rapid-acting version of insulin aspart (Fiasp, Novo Nordisk) for use in insulin pumps. Injectable and intravenous ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. This medicine is new or being used ...
The approval was based on data from an active-controlled, treat-to-target trial (Onset7) that included 777 pediatric patients (aged 2 to 17 years) with type 1 diabetes. The Food and Drug ...
The FDA approved Novo Nordisk’s Fiasp, an insulin aspart injection to be used as a mealtime insulin option for children with diabetes, the company announced Jan. 6. Fiasp is the first and only ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. This medicine is new or being used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results